Trial Profile
KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; KAND-567 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms kandova
- Sponsors Kancera
- 23 Feb 2024 According to an Kancera media release, the company's goal is to complete the Phase Ib part of the studies in the second quarter of 2024 and to present initial results in the fourth quarter of 2024.
- 17 Nov 2023 According to a Kancera media release, top line results are expected before year end 2024. The company expects that the seven hospitals that will be active in phase IIa will be capable of recruiting approximately 2-4 patients each.
- 17 Nov 2023 According to a Kancera media release, approval of this study amended protocol is expected during the first quarter 2024. The company expects that the amended protocol will increase the recruitment of patients and the goal to roll over to phase IIa during the second quarter next year thereby remains.